相关产品推荐更多 >
万千商家帮你免费找货
0 人在求购买到急需产品
相关阅读
Dove 医学期刊 APC 折后约 1.95w,中国大陆作者专享AJE 润色 84 折,送京东卡等福利,优惠码 DXYAJE五大应用案例:Mustang Q 膜层析应用全解析1 个小工具,一次性搞定流程图、质粒图谱和信号通路图- 详细信息
- 文献和实验
- 技术资料
- 靶点:
F3
- 应用范围:
ELISA (Verified)
- 宿主:
Rabbit
- 适应物种:
Rat
- 标记物:
Unconjugated
- 克隆性:
polyclonal
- 保存条件:
stored at 2℃-8℃ for one month, stored at -20℃ to -80℃ for one year.
- 形态:
See the lable
- 亚型:
liquid
- 免疫原:
IgG
- 规格:
10/50/100/200 ul
风险提示:丁香通仅作为第三方平台,为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全,合理判断,谨慎选购商品,商家和用户对交易行为负责。对于医疗器械类产品,请先查证核实企业经营资质和医疗器械产品注册证情况。
文献和实验Identification of Mutations in the Human Factor VII Gene
It has been recognized from the early 1800s that activation of coagulation can be initiated by the exposure of subendothelial layers (tissue factor), but it was the 1940s before factor VII (FVII) was included in this event
Studies on Coagulation Incompatibilities for Xenotransplantation
) circulating PC in the presence of thrombin. Tissue factor pathway inhibitor (TFPI), is the primary inhibitor of tissue factor (TF)-induced coagulation. TFPI directly inhibits the activated factor X (FXa) and blocks the procoagulant activity of the TF/factor
2141-V11瘤内给药2例CR、Dapirolizumab III期BICLA 50%:CD40在2026年交出怎样的答卷
CD40-CD40L通路是连接先天性与适应性免疫的核心共刺激轴,但其临床开发长期受制于系统性给药的剂量限制性毒性。2025–2026年,这一困局出现了方向性松动:肿瘤领域不再执着于全身性CD40激动剂,而是转向FAP×CD40双特异性DARPin/抗体与瘤内给药,在实现肿瘤微环境重塑的同时将全身毒性降至最低;自身免疫领域则凭借Fc沉默/Fc工程化的第二代CD40L抑制剂,接连在SLE与干燥综合征的III期试验中取得阳性结果。机制层面,CMTM6维持B细胞膜CD40稳定性、以及CD40双表位抗体
技术资料暂无技术资料 索取技术资料






